A homegrown Northwestern drug is giving Chicago-area families something they almost never get with metastatic pancreatic cancer: more time. In a randomized phase 2 trial, patients who received the experimental drug elraglusib along with standard chemotherapy were about twice as likely to be alive at one year as those who got chemotherapy alone, a rare bit of good news in a disease that often claims lives within months. The study, led by Northwestern Medicine and published Tuesday, is offering cautious hope rather than headlines about miracles, but for many families that is more than enough.
Trial shows survival benefit
The international phase 2 study enrolled patients at more than 60 sites and found a clear survival edge for the combination treatment. In the modified intention-to-treat analysis, median overall survival reached 10.1 months with elraglusib plus gemcitabine/nab-paclitaxel, compared with 7.2 months on chemotherapy alone. The 12-month survival rate climbed from 22.3% to 44.1%, according to Nature Medicine. The paper reports a hazard ratio for death of 0.62, a statistically significant difference that the authors say justifies moving ahead to a larger trial.
Chicago roots and patient stories
Northwestern Medicine led the research, and university materials note that elraglusib was developed in Northwestern laboratories and tested at the Robert H. Lurie Comprehensive Cancer Center. Relatives of trial participants described gaining extra months together and said that enrolling in the study “gave us something to focus on,” according to the university release. Local coverage of the results in Crain's Chicago Business and the university news release adds a distinctly Chicago angle, from lab benches in the city to patients being treated just blocks from the lakefront.
How elraglusib works and safety
Elraglusib is a GSK-3β inhibitor that appears to act on the tumor microenvironment and to boost cancer-killing immune cells, an effect the study's correlative analyses observed in treated tumors. The trial documented higher rates of neutropenia and other treatment-emergent adverse events in the elraglusib arm, but the authors describe the overall safety profile as manageable, according to Nature Medicine. Actuate Therapeutics, which funded the study, said it has provided updated clinical data to regulators and is preparing next steps for development, according to Actuate Therapeutics.
Why this matters
Pancreatic cancer remains one of the deadliest common cancers, and five-year relative survival in the United States sits only in the low teens. In that context, any improvement at the one-year mark stands out. SEER data put five-year relative survival for pancreatic cancer (2015–2021) at about 13.3%, which underscores why a doubled 12-month survival rate is meaningful for patients and the oncologists treating them. At the same time, specialists are quick to point out that phase 2 signals, no matter how promising, need confirmation in larger, randomized phase 3 trials before anyone talks about changing the standard of care.
What's next for the drug
Company filings say a phase 3 confirmatory trial is in the planning stages, although broader testing will depend on funding, partnerships, and ongoing discussions with regulators. Actuate's SEC filing notes that the firm has updated the FDA with the trial dataset and is weighing its next regulatory moves, while cautioning that the results are preliminary and forward-looking.
“Pancreatic cancer remains one of the most challenging solid tumors to treat, but these findings provide cautious optimism for patients,” study lead Dr. Devalingam Mahalingam said in the university's news release. For Chicago patients and families, the message right now is guarded hope: the results matter, but a larger trial will have to deliver before elraglusib can move from experimental lifeline to standard treatment option.
